“Double-Hit” Chronic Lymphocytic Leukemia, Involving the TP53 and MYC Genes - Sorbonne Université
Article Dans Une Revue Frontiers in Oncology Année : 2022

“Double-Hit” Chronic Lymphocytic Leukemia, Involving the TP53 and MYC Genes

Résumé

Although the 17p deletion [del(17p)] is rare in cases of treatment-naive chronic lymphocytic leukemia (CLL), its frequency is higher in refractory/relapsed CLLparticularly in patients undergoing chemo(immuno)therapy. TP53 disruption (deletion and/or mutation) is the strongest prognostic factor for refractoriness to chemotherapy; the use of Bruton tyrosine kinase inhibitors and BCL2 inhibitors is then indicated. Rare cases of CLL can also harbor translocation or gain of the MYC oncogene. "Double-hit CLL" (with del(17p) and MYC gain) is associated with a very poor prognosis. The prognostic impact of TP53 disruption with MYC aberrations in patients receiving targeted therapies must now be evaluated.

Domaines

Cancer
Fichier principal
Vignette du fichier
fonc-11-826245.pdf (467.74 Ko) Télécharger le fichier
Origine Publication financée par une institution

Dates et versions

hal-03551259 , version 1 (01-02-2022)

Identifiants

Citer

Florence Nguyen-Khac. “Double-Hit” Chronic Lymphocytic Leukemia, Involving the TP53 and MYC Genes. Frontiers in Oncology, 2022, 11, ⟨10.3389/fonc.2021.826245⟩. ⟨hal-03551259⟩
55 Consultations
36 Téléchargements

Altmetric

Partager

More